Background: This study sought to establish a rat model of hypoparathyroidism by removing the rat parathyroid glands, and compare the effects of different transplantation sites and transplantation methods using a primary culture of parathyroid cells in vitro on the hormone secretion of the model rats.Methods: Male Sprague Dawley (SD) rats were selected for in vivo parathyroid gland removal, and rats with abnormal postoperative water intake, weight gain, parathyroid hormone (PTH), and blood calcium ion concentration were selected as transplant recipients and divided into the model group, brachioradialis muscle cell transplantation group, gelatin sponge group, and subcutaneous transplantation group. The parathyroid tissue was removed and the primary cell culture was performed in vitro using homozygous SD rats as graft donors. When the parathyroid cells were able to secrete PTH, transplantation was performed, and the postoperative recovery of the PTH function of the rats with different transplantation sites and methods were observed.Results: A recipient model with low PTH was successfully established, and parathyroid progenitor cells with obvious PTH secretion were obtained. Better secretion was observed in the brachioradialis cell group compare with other groups. Conclusions:The in vitro primary cell culture of the donor parathyroid cells combined with cell transplantation significantly improved the physiological function of the hypoparathyroid rats, and could potentially replace traditional clinical brachioradialis muscle tissue transplantation.

Purpose:TGF-β1 and TGF-βR1 participate in regulation of the host’s immune system and inflammatory responses and may serve as prognostic biomarkers for HPV-associated OPSCC. Experimental Design: This study included 1013 patients with incident OPSCC, of whom 489 had tumor HPV16 status determined. All patients were genotyped for two functional polymorphisms: TGF-β1 rs1800470 and TGF-βR1 rs334348. Univariate and multivariate Cox regression models were performed to evaluate associations between the polymorphisms and OS, DSS, and DFS. Results: Patients with TGF-β1rs1800470 CT or CC genotype had significantly 70%-80% reduced risks of OS, DSS, and DFS compared with patients with TT genotype, and patients with TGF-βR1rs334348 GA or GG genotype had significantly 30%-40% reduced risks of OS, DSS, and DFS compared with patients with AA genotype. Furthermore, among patients with HPV-positive OPSCC, the same patterns were observed but the risk reductions were greater: up to 80%-90% for TGF-β1rs1800470 CT or CC genotype and 70%-85% for TGF-βR1rs334348 GA or GG genotype. The risk reductions were greater still, up to 17-25 times reduced, for patients with both TGF-β1rs1800470 CT or CC genotype and TGF-βR1rs334348 GA or GG genotype compared to patients with both TGF-β1rs1800470 TT genotype and TGF-βR1rs334348 AA genotype among patients with HPV-positive OPSCC. Conclusions: Our findings indicate that TGF-β1rs1800470 and TGF-βR1rs334348 may individually or jointly modify risks of death and recurrence in patients with OPSCC, particularly those with HPV-positive OPSCC patients undergoing definitive radiotherapy, and may serve as prognostic biomarkers, which could lead to better personalized treatment and improved prognosis.

No abstract